TSE:AUP

Aurinia Pharmaceuticals Stock Forecast, Price & News

C$15.44
-0.35 (-2.22 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
C$15.43
Now: C$15.44
C$15.77
50-Day Range
C$15.48
MA: C$16.65
C$18.41
52-Week Range
C$15.18
Now: C$15.44
C$26.23
Volume53,800 shs
Average Volume171,757 shs
Market CapitalizationC$1.97 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

Industry, Sector and Symbol

Industry Technical & System Software
Sub-IndustryN/A
CUSIPN/A
CIKN/A
Phone+1-250-7084272
Employees294
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$50.12 million
Cash FlowC$3.01 per share
Book ValueC$3.22 per share

Profitability

Miscellaneous

Market CapC$1.97 billion
Next Earnings Date5/13/2021 (Estimated)
OptionableNot Optionable

Headlines

AUPH Apr 2021 12.000 put
March 22, 2021 |  uk.finance.yahoo.com
CANADA STOCKS - TSX rises 0.24% to 17,887.96
January 25, 2021 |  nasdaq.com
Why Aurinia Pharmaceuticals Stock Is Flying Today
January 25, 2021 |  finance.yahoo.com
CANADA STOCKS - TSX rises 0.2% to 17,945.11
January 19, 2021 |  nasdaq.com
My Top Six 2020 Stock Picks Gained an Average of 75%
December 30, 2020 |  finance.yahoo.com
Is AUPH A Good Stock To Buy According To Hedge Funds?
December 21, 2020 |  finance.yahoo.com
Why Aurinia's Stock Is Trading Lower Today
December 17, 2020 |  benzinga.com
See More Headlines

MarketRank

Overall MarketRank

0.89 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
C$15.44
-0.35 (-2.22 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AUP News and Ratings via Email

Sign-up to receive the latest news and ratings for AUP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Aurinia Pharmaceuticals (TSE:AUP) Frequently Asked Questions

Is Aurinia Pharmaceuticals a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Aurinia Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AUP, but not buy additional shares or sell existing shares.
View analyst ratings for Aurinia Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Aurinia Pharmaceuticals?

Wall Street analysts have given Aurinia Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Aurinia Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Aurinia Pharmaceuticals' next earnings date?

Aurinia Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 13th 2021.
View our earnings forecast for Aurinia Pharmaceuticals
.

How has Aurinia Pharmaceuticals' stock been impacted by Coronavirus?

Aurinia Pharmaceuticals' stock was trading at C$19.38 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AUP stock has decreased by 20.3% and is now trading at C$15.44.
View which stocks have been most impacted by COVID-19
.

Who are Aurinia Pharmaceuticals' key executives?

Aurinia Pharmaceuticals' management team includes the following people:
  • Mr. Peter S. Greenleaf M.B.A., Pres, CEO & Director (Age 51, Pay $1.06M)
  • Dr. Neil Solomons M.D., Chief Medical Officer
  • Mr. Matthew Maxwell Donley M.B.A., Exec. VP of Internal Operations & Strategy (Age 52, Pay $544.83k)
  • Mr. Michael R. Martin, Co-Founder & COO
  • Mr. Joseph M. Miller CPA, Chief Financial Officer (Age 47)
  • Dr. Glenn Schulman, Sr. VP of Corp. Communications & Investor Relations
  • Mr. Stephen P. Robertson, Exec. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer
  • Dr. Robert B. Huizinga M.Sc., Ph.D., RN NNC, MSc(Epi), CNeph(C), Exec. VP of Corp. Devel.
  • Mr. Chris Hays, VP of Marketing
  • Mr. Fran Lynch, VP of Sales

Who are some of Aurinia Pharmaceuticals' key competitors?

What other stocks do shareholders of Aurinia Pharmaceuticals own?

What is Aurinia Pharmaceuticals' stock symbol?

Aurinia Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "AUP."

How do I buy shares of Aurinia Pharmaceuticals?

Shares of AUP and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Aurinia Pharmaceuticals' stock price today?

One share of AUP stock can currently be purchased for approximately C$15.44.

How much money does Aurinia Pharmaceuticals make?

Aurinia Pharmaceuticals has a market capitalization of C$1.97 billion and generates C$50.12 million in revenue each year.

How many employees does Aurinia Pharmaceuticals have?

Aurinia Pharmaceuticals employs 294 workers across the globe.

What is Aurinia Pharmaceuticals' official website?

The official website for Aurinia Pharmaceuticals is www.auriniapharma.com.

Where are Aurinia Pharmaceuticals' headquarters?

Aurinia Pharmaceuticals is headquartered at 1203-4464 Markham St, VICTORIA, BC V8Z 7X8, Canada.

How can I contact Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals' mailing address is 1203-4464 Markham St, VICTORIA, BC V8Z 7X8, Canada. The company can be reached via phone at +1-250-7084272.


This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.